Rosaline Chung-Yee Hui

Rosaline Chung-Yee Hui


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CYChin-Yi Yang
Chin-Yi Yang
PLPo-Ju Lai
Po-Ju Lai
CCChun-Bing Chen
Chun-Bing Chen
TCTom C. Chan
Tom C. Chan
RHRosaline Chung-Yee Hui
Rosaline Chung-Yee Hui
WCWenHung Chung
WenHung Chung
To determine phenotype-related dupilumab response in adult patients with atopic dermatitis (AD), this multicenter, retrospective study included 111 adults with moderate-to-severe AD in Taiwan, with median age of 31.5 years (18–87) and 71 (64.0%) males. Patients received dupilumab 300 mg per two to three weeks up to 12 months. We found a significant improvement after 4 and 16 weeks of treatment in all patients for all the assessed scores, including eczema area and severity index (EASI) improvement ≥50% (EASI-50) and 75% (EASI-75), EASI reaching minimal clinically important difference (MCID), and Investigator’s Global Assessment (IGA) improvement ≥2. Importantly, prior to asthma, early AD onset and 3-week drug intervals were significantly associated with a high proportion of EASI-75 at month 12, while prurigo and lichenoid phenotypes were associated with a lower proportion of EASI-75 at month 12. However, the majority of adverse events were mild in severity. In conclusion, our study results identify phenotype-related dupilumab response at month 12 in adults with moderate-to-severe AD, and we suggest that treatment should not be discontinued until reaching a satisfactory clinical response.

4 September 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HTHao-Chih Tai
Hao-Chih Tai
YLYi-Hua Liao
Yi-Hua Liao
YCYa-Ching Chang
Ya-Ching Chang
CYChin-Yi Yang
Chin-Yi Yang
SHShyue-Yih Horng
Shyue-Yih Horng
CCChang-Yi Chou
Chang-Yi Chou
Background: Hypersensitivity to the new dermal injectable porcine-based collagen with lidocaine featuring a novel cross-linking technology (test filler) for nasolabial fold correction was compared to the commercially available traditional cross-linked dermal injectable porcine-based collagen with lidocaine (control filler). Methods: Recruited participants (n = 279) received a single 0.1 mL intradermal injection of either test filler or control filler in the left forearm as a screening skin allergy test. Injection sites were assessed clinically at 24 h post-implant. Treatment was given to 252 successfully screened participants, and injection sites were monitored for 21 days. Immunological examinations were performed at screening and then at 4 and 24 weeks post-treatment. Observations for adverse events continued until the 52nd week. Results: Intradermal allergy testing results were negative for all the test recipients (0/124) and positive for two control recipients (2/132, 1.5%). Most of the participants exhibited no changes in serum immunoglobulin (IgG, IgM) and complement (C3, C4) levels. No serious adverse events related to the device were recorded. Most adverse events were common complications of dermal filler treatment and were related to the injection site. Most adverse effects were resolved or under control by 52 weeks. Conclusions: Hypersensitivity reactions with the test filler were lower than those with the control filler, validating the safe use of test filler for nasolabial fold correction without the need for pretreatment skin testing.

1 December 2018 in Dermatologica Sinica
Verified
Journal Article
Open access
CYChi-Feng Yen
Chi-Feng Yen
WFWen-Lang Fan
Wen-Lang Fan
CWChuang-Wei Wang
Chuang-Wei Wang
SSShih-Chi Su
Shih-Chi Su
WCWen-Hung Chung
Wen-Hung Chung
RHRosaline Chung-Yee Hui
Rosaline Chung-Yee Hui